EUVIMED · CrossrefJournal
The Lancet Neurology
ISSN 1474-4422 · Elsevier BV
Latest articles
Dravet syndrome: clinical features across the lifespan, molecular findings, and therapeutic approaches
Neuropathic pain: advances in diagnosis, mechanisms, and treatment
Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial
Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study
GBA1 Parkinson's disease: peculiarities in Asia and India
Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial
Dravet syndrome: modifying disease across the lifespan
CSF dynamics in idiopathic normal pressure hydrocephalus
CSF dynamics in idiopathic normal pressure hydrocephalus
CAR T-cell trials paused after three deaths
Middle meningeal artery embolisation for chronic subdural haematoma
Rethinking migraine prevalence in women and men
Wise use of the optic nerve in multiple sclerosis diagnosis
The ADORE trial results and the ongoing edaravone debate
Bridging the gap between dementia risk factors and interventions
Bridging the gap between dementia risk factors and interventions
GBA1 Parkinson's disease: peculiarities in Asia and India
Rethinking recruitment to clinical trials in Alzheimer's disease
Patricia Pozo-Rosich: making migraine visible
Heela Hareer
A seat at the table—and making room for others
Finding the art in science within the EAN community
Safety, tolerability, and efficacy of bepranemab in people living with prodromal-to-mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 trial
Anticoagulants compared with aspirin in patients with embolic strokes of undetermined source: an individual participant data meta-analysis of randomised trials
Correction to Lancet Neurol 2026; 25: 1061
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial
Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities
EUVIMED